Case Study on Gliead’s Blockbuster Veklury – Sales and Strategic Planning
Posted on30 Oct 2020
Tagsgilead, Gilead Sciences, pharma strategic deal, Remdesivir, Strategic deal in pharma, strategic management in pharma, Veklury
Comments0
FDA approved Veklury (remdesivir), the first drug approved to treat COVID-19, for use in adults and pediatric patients 12 years of age... Read More
Sanofi and Merck to conduct phase 2 trial of THOR-707 in combo with Keytruda
Sanofi has entered into an agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada)... Read More
MHRA UK inititated rolling review process of Moderna’s mRNA Covid-19 vaccine
Posted on30 Oct 2020
Comments0
Moderna, a biotechnology company, announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has started the rolling... Read More
Understanding on India’s Revised Patent Rules On Priority filing w.e.f 19 October, 2020
The Indian Patent office has issued a notification that the Patents (Amendment) Rules, 2020, was released and enforced on 19 October, 2020.... Read More
Insight of BioInvent’s licensing deal of anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals
BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region. BioInvent have entered into an exclusive licensing agreement for the... Read More
Case Study – Inmazeb: USFDA Approval of first ebola medicine
U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a combination of three monoclonal antibodies, as the first FDA-approved treatment... Read More
Pfizer’s Hospital Business acquires Arixa Pharma
Posted on24 Oct 2020
Comments0
Arixa Pharmaceuticals, a company developing next-generation oral antibiotics for drug-resistant Gram-negative infections announced that Pfizer’s Hospital Business has agreed to acquire Arixa.... Read More
Insight on Veklury’s clinical and strategic pathway for USFDA approval for Covid-19
Posted on24 Oct 2020
TagsCOVID-19, priority review, Priority Review Designation, Remdesivir, usfda, usfda accelerated approval, USFDA Priority Review, Veklury
Comments0
USFDA approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at... Read More
Case Study: Rinvoq’s brand Dermatology market expansion strategy
Rinvoq is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Rinvoq is the brand of... Read More